Ergot derivatives for Parkinsonism

D. B. Calne, A. C. Williams, J. G. Nutt, A. Neophytides, T. Eisler, P. F. Teychenne

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The response of Parkinsonism to three ergot derivatives which modify dopaminergic transmission was studied. CF 25-397 behaved more as an antagonist than an agonist. Lergotrile was an agonist with therapeutic properties marred by prominent hepatotoxicity. Bromocriptine is an effective anti-Parkinsonian agent, particularly useful in patients with prominent dyskinesia or 'on-off' reactions to levodopa; in most patients optimal results have been obtained by combining from 40 to 90 mg of bromocriptine daily with approximately 60% of the previous maximal dose of levodopa. Unfortunately, only some 50% of patients tolerate long-term bromocriptine therapy, but all adverse reactions have been dose dependent and reversible.

Original languageEnglish (US)
Pages (from-to)25-26
Number of pages2
JournalUnknown Journal
Issue numberSuppl. 3
StatePublished - 1979
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Ergot derivatives for Parkinsonism'. Together they form a unique fingerprint.

Cite this